Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection

Vaccine

Volumn 26, Issue 13, 2008, Pages 1644-1651

  Du, Lanying ^a,c   Zhao, Guangyu ^b   Lin, Yongping ^a   Chan, Chris ^a   He, Yuxian ^c   Jiang, Shibo ^c   Wu, Changyou ^d   Jin, Dong Yan ^a   Yuen, Kwok Yung ^a   Zhou, Yusen ^b   Zheng, Bo Jian ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adeno associated virus; Immune responses; Peptides to T cell epitopes; Receptor binding domain; SARS CoV

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN HEK293; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIROLOGY; VIRUS STRAIN;

ANIMALS; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECEPTORS, VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 40249111494     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.025     Document Type: Article

References (33)

1. Orellana C. Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 4 2 (2004) 64
2. Normile D. Infectious diseases Mounting lab accidents raise SARS fears. Science 304 5671 (2004) 659-661
3. Normile D. Infectious diseases SARS experts want labs to improve safety practices. Science 302 5642 (2003) 31
4. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 5748 (2005) 676-679
5. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M., et al. Mucosal immunisation of african green monkeys (cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 9427 (2004) 2122-2127
6. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101 26 (2004) 9804-9809
7. He Y., Lu H., Siddiqui P., Zhou Y., and Jiang S. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174 8 (2005) 4908-4915
8. He Y., Zhou Y., Liu S., Kou Z., Li W., Farzan M., et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 324 2 (2004) 773-781
9. Kong W.P., Xu L., Stadler K., Ulmer J.B., Abrignani S., Rappuoli R., et al. Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. J Virol 79 22 (2005) 13915-13923
10. Ma C., Yao K., Zhou F., and Zhu M. Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene. Cell Mol Immunol 3 6 (2006) 459-465
11. Du L., He Y., Wang Y., Zhang H., Ma S., Wong C.K., et al. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines. Virology 353 1 (2006) 6-16
12. Zhi Y., Kobinger G.P., Jordan H., Suchma K., Weiss S.R., Shen H., et al. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology 335 1 (2005) 34-45
13. Huang J., Cao Y.N., Du J.L., Bu X.Z., Ma R., and Wu C.Y. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4 + and CD8 + T cells promote cellular immune responses. Vaccine 25 39-40 (2007) 6981-6991
14. Mancheno-Corvo P., and Martin-Duque P. Viral gene therapy. Clin Transl Oncol 8 12 (2006) 858-867
15. Du L., Zhao G., He Y., Guo Y., Zheng B.J., Jiang S., et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25 15 (2007) 2832-2838
16. Zheng B.J., Wong K.H., Zhou J., Wong K.L., Young B.W., Lu L.W., et al. SARS-related virus predating SARS outbreak, Hong Kong. Emerg Infect Dis 10 2 (2004) 176-178
17. Zheng B.J., Guan Y., Tang Q., Du C., Xie F.Y., He M.L., et al. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir Ther 9 3 (2004) 365-374
18. Chan V.S., Chan K.Y., Chen Y., Poon L.L., Cheung A.N., Zheng B., et al. Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nat Genet 38 1 (2006) 38-46
19. Keng C.T., Zhang A., Shen S., Lip K.M., Fielding B.C., Tan T.H., et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol 79 6 (2005) 3289-3296
20. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (2004) 561-564
21. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78 22 (2004) 12672-12676
22. He Y., Li J., Heck S., Lustigman S., and Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol 80 12 (2006) 5757-5767
23. Jiang S., He Y., and Liu S. SARS vaccine development. Emerg Infect Dis 11 7 (2005) 1016-1020
24. He Y., and Jiang S. Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol 18 2 (2005) 327-332
25. Woo P.C., Lau S.K., Tsoi H.W., Chen Z.W., Wong B.H., Zhang L., et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine 23 42 (2005) 4959-4968
26. Zakhartchouk A.N., Liu Q., Petric M., and Babiuk L.A. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23 35 (2005) 4385-4391
27. Chunling M., Kun Y., Jian X., Jian Q., Hua S., and Minsheng Z. Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice. Intervirology 49 5 (2006) 307-318
28. Xin K.Q., Ooki T., Mizukami H., Hamajima K., Okudela K., Hashimoto K., et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther 13 13 (2002) 1571-1581
29. Kuck D., Lau T., Leuchs B., Kern A., Muller M., Gissmann L., et al. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 80 6 (2006) 2621-2630
30. Wang Z., Allen J.M., Riddell S.R., Gregorevic P., Storb R., Tapscott S.J., et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of duchenne muscular dystrophy. Hum Gene Ther 18 1 (2007) 18-26
31. Riviere C., Danos O., and Douar A.M. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13 17 (2006) 1300-1308
32. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., and Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4 12 (2003) 1191-1198
33. Roberts A.D., Ely K.H., and Woodland D.L. Differential contributions of central and effector memory T cells to recall responses. J Exp Med 202 1 (2005) 123-133